Epidermolysis Bullosa (EB) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Epidermolysis Bullosa Emerging Therapy and TPP Insights

Thelansis’s “Epidermolysis Bullosa (EB) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Epidermolysis Bullosa Overview

Epidermolysis bullosa (EB) is a group of inherited disorders in which defects in proteins that anchor or stabilize the skin cause extreme fragility and blistering after friction or trauma. Depending on the subtype, skin separation occurs within the epidermis, basement membrane zone, or dermis. Severe forms can produce chronic wounds, scarring, infections, nutritional problems, anemia, esophageal strictures, and pain, while some dystrophic forms carry a high risk of cutaneous squamous cell carcinoma. Care centers on wound management, infection prevention, pain control, nutritional support, and treatment of complications. Options are emerging: beremagene geperpavec (Vyjuvek), a topical gene therapy delivering COL7A1, is approved in the U.S. for wounds in COL7A1-related dystrophic EB; prademagene zamikeracel (Zevaskyn), an autologous cell-sheet gene therapy, is approved for wounds in recessive dystrophic EB; and Filsuvez is approved for wounds associated with dystrophic or junctional EB.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)